Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

  • End date
    Jul 7, 2029
  • participants needed
  • sponsor
    Erasmus Medical Center
Updated on 7 July 2022
cancer chemotherapy
resectable pancreatic cancer
pancreatic ductal adenocarcinoma
breast ductal carcinoma


The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2).

The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.

Condition Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Treatment fluorouracil, Leucovorin calcium, Oxaliplatin, irinotecan hydrochloride, Resection
Clinical Study IdentifierNCT04927780
SponsorErasmus Medical Center
Last Modified on7 July 2022


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically (Bethesda 5 or 6) confirmed pancreatic ductal adenocarcinoma
Resectable tumor according to Dutch Pancreatic Cancer Group criteria: no arterial contact and venous contact with the superior mesenteric vein or portal vein of 90 degrees or less
No evidence for metastatic disease
WHO performance status of 0 or 1
Ability to undergo surgery and mFOLFIRINOX chemotherapy
Leucocytes (WBC) ≥ 3.0 x 10^9/L
Platelets ≥ 100 x 10^9/L
Hemoglobin ≥ 6.0 mmol/l
Renal function: eGFR ≥ 40 ml/min
Age ≥ 18 years
Written informed consent

Exclusion Criteria

Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer
Prior chemotherapy precluding mFOLFIRINOX
Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) <2cm, and gastrointestinal stromal tumor (GIST) <2cm), unless no evidence of disease and diagnosed more than 3 years before diagnosis of pancreatic cancer, or with a life expectancy of more than 5 years from date of inclusion
Pregnancy or lactation
Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note